Rocket Pharmaceuticals (RCKT) incurred a loss of 56 cents per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 59 cents. The company reported a loss of 66 cents per share in the year-ago quarter.In the absence of a marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the reported quarter. The Zacks Consensus Estimate for the company’s total revenues was $8 million. (See the Zacks Earnings Calendar to stay ahead of market-making n ...

Exhibit 99.1 Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress Phase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025 Initial data from the Phase 1 study of RP-A601 for PKP2-ACM anticipated May 2025 IND submission for BAG3-DCM program expected mid-year 2025 Sarbani Chaudhuri appointed Chief Commercial & Medical Af airs Of icer Cash, cash equivalents and investments of approximately $318.2M; expected operational ru ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (609) 659-8001 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Commission File Numb ...

Rocket Pharmaceuticals (NASDAQ: RCKT ) is a compelling gene therapy story with two differentiating factors. First, Rocket's therapies seemingly offer a life-long effect as they target cardiovascular and hematology, whereas many gene therapies (especially those targeting liver) display limited durability. Second, theAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or ...

Rocket Pharmaceuticals (RCKT) incurred a loss of 62 cents per share in the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 71 cents. In the year-ago quarter, the company reported a loss of 64 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.In the absence of any marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues in the fourth quarter.In the past year, shares of Rocket Pharmaceuticals have plunged ...

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress Dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease; Program update expected in the first half of 2025 New England Journal of Medicine publication of Phase 1 study of RP-A501 to treat patients with Danon disease Long-term data from the Phase 1 trial of RP-A501 for Danon disease presented at AHA on safety and meaningful ef icacy Enrollment completed in low dose cohort of Phas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36829 Rocket Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3475813 (State or Other Jurisdic ...

I interviewed Rocket Pharmaceuticals, Inc.’s (NASDAQ: RCKT ) CEO Dr. Gaurav Shah a year ago, but apart from that, I haven’t covered it in 2 years. My last coverage was from February 2023. Back in 2024, RCKT hadAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring ...

A downtrend has been apparent in Rocket Pharmaceuticals (RCKT) lately with too much selling pressure. The stock has declined 12.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicat ...

Key TakeawaysJefferies initiated a "buy" rating on Rocket Pharmaceuticals based on the biotech firm's experimental gene therapies.Jefferies also set a price target of $29.The analysts said they were especially optimistic about Rocket's treatment for a rare genetic heart condition, which they believe could be a $1 billion opportunity for the company. Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism ab ...